- Home
- SKYH vs NGNE Comparison
SKYH vs NGNE Comparison
Compare SKYH & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYH
- NGNE
- Stock Information
- Founded
- SKYH 2017
- NGNE 2003
- Country
- SKYH United States
- NGNE United States
- Employees
- SKYH N/A
- NGNE N/A
- Industry
- SKYH Military/Government/Technical
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- SKYH Industrials
- NGNE Health Care
- Exchange
- SKYH Nasdaq
- NGNE Nasdaq
- Market Cap
- SKYH 325.2M
- NGNE 325.3M
- IPO Year
- SKYH N/A
- NGNE N/A
- Fundamental
- Price
- SKYH $10.52
- NGNE $18.48
- Analyst Decision
- SKYH Strong Buy
- NGNE Strong Buy
- Analyst Count
- SKYH 3
- NGNE 7
- Target Price
- SKYH $14.83
- NGNE $41.86
- AVG Volume (30 Days)
- SKYH 104.9K
- NGNE 110.1K
- Earning Date
- SKYH 08-12-2025
- NGNE 08-11-2025
- Dividend Yield
- SKYH N/A
- NGNE N/A
- EPS Growth
- SKYH N/A
- NGNE N/A
- EPS
- SKYH N/A
- NGNE N/A
- Revenue
- SKYH $20,919,000.00
- NGNE N/A
- Revenue This Year
- SKYH $124.39
- NGNE N/A
- Revenue Next Year
- SKYH $83.05
- NGNE N/A
- P/E Ratio
- SKYH N/A
- NGNE N/A
- Revenue Growth
- SKYH 94.38
- NGNE N/A
- 52 Week Low
- SKYH $9.28
- NGNE $6.88
- 52 Week High
- SKYH $14.52
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- SKYH 52.98
- NGNE 35.93
- Support Level
- SKYH $10.20
- NGNE $19.59
- Resistance Level
- SKYH $10.89
- NGNE $20.46
- Average True Range (ATR)
- SKYH 0.40
- NGNE 1.23
- MACD
- SKYH 0.02
- NGNE -0.20
- Stochastic Oscillator
- SKYH 46.43
- NGNE 13.37
About SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.